Overview

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

Status:
NOT_YET_RECRUITING

Trial end date:
2031-04-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.

Phase:

PHASE1

Details

Lead Sponsor:

EG 427

Treatments:

Patient Reported Outcome Measures
Urodynamics